DIR22 Antibody

Shipped with Ice Packs
In Stock

Description

Overview of CD22 as a Therapeutic Target

CD22 is a B-lineage differentiation antigen expressed from early progenitor stages (pro-B cells) until terminal differentiation into plasma cells . It is a validated target for monoclonal antibody therapies in B-cell malignancies, including acute lymphoblastic leukemia (ALL) and non-Hodgkin’s lymphoma (NHL) . Key properties include:

  • Universal expression: Detected in 100% of relapsed/refractory pre-B ALL cases .

  • Surface density: Median 3,470 sites/cell (range: 349–19,653) .

  • Stability: No antigenic loss observed post-anti-CD22 therapy in serial studies .

Anti-CD22 Antibody Therapeutics

Multiple anti-CD22 antibodies have been developed, with distinct mechanisms and clinical applications:

Table 1: Key Anti-CD22 Antibodies in Clinical Development

Antibody NameFormatConjugate/LinkerIndicationsClinical Phase/Status
EpratuzumabHumanized IgG1UnconjugatedAggressive NHL, autoimmune diseasesPhase I/II completed
Inotuzumab ozogamicinHumanized IgG4Calicheamicin (ADC)Relapsed/refractory ALLFDA-approved
Moxetumomab pasudotoxAnti-CD22 immunotoxinPseudomonas exotoxin AHairy cell leukemiaFDA-approved

Binding and Internalization

  • Affinity: Epratuzumab binds CD22 with KD = 0.7 nM .

  • Internalization: Rapid uptake observed in Burkitt lymphoma cell lines and primary B-cells .

  • Signaling: Induces CD22 phosphorylation, though downstream effects remain unclear .

Pharmacodynamic Effects

  • B-cell depletion: Anti-CD22 antibody-drug conjugates (ADCs) reduce proliferating B-cells in primates .

  • Synergy with CD79b targeting: Combined CD22/CD79b ADCs enhance cytotoxicity in NHL models .

Table 2: Epratuzumab Phase I/II Trial Results (NHL)

ParameterResult
Dose range120–1,000 mg/m² weekly ×4 weeks
Objective response rate10% (5/56 patients)
Complete responses3/56 patients
Median response duration26.3 weeks
Safety profileNo dose-limiting toxicity observed

Analytical Methods for Anti-CD22 Antibodies

A cell membrane-based ELISA was developed to quantify anti-CD22 antibodies using Raji cell membrane antigens :

  • EC₅₀: 28.3 μg/mL for chimeric anti-CD22 antibodies .

  • Specificity: No cross-reactivity with irrelevant antibodies (e.g., anti-TNFα) .

  • Reproducibility: Intra-assay CV = 10% .

Challenges and Limitations

  • MLL-rearranged ALL: Subpopulations of CD22-negative blasts may limit single-agent efficacy .

  • Soluble CD22: Low levels in circulation (<1 μg/mL) minimize pharmacokinetic interference .

Future Directions

  • Combination therapies: Pairing anti-CD22 antibodies with anti-CD20 (e.g., rituximab) or chemotherapy .

  • Next-gen ADCs: Optimizing linker-drug systems (e.g., MC-vc-PAB-MMAE) for improved payload delivery .

Product Specs

Buffer
Preservative: 0.03% ProClin 300
Components: 50% Glycerol, 0.01M Phosphate Buffered Saline (PBS), pH 7.4
Form
Liquid
Lead Time
14-16 week lead time (made-to-order)
Synonyms
DIR22 antibody; At3g13660 antibody; MMM17 antibody; Dirigent protein 22 antibody; AtDIR22 antibody
Target Names
DIR22
Uniprot No.

Target Background

Function

DIR22 antibody targets proteins that direct stereoselectivity in the phenoxy radical-coupling reaction. This reaction produces optically active lignans from two coniferyl alcohol molecules. DIR22's target protein plays a crucial role in the biosynthesis of lignans, flavonolignans, and alkaloids, thus contributing significantly to plant secondary metabolism.

Database Links

KEGG: ath:AT3G13660

STRING: 3702.AT3G13660.1

UniGene: At.50180

Protein Families
Plant dirigent protein family
Subcellular Location
Secreted, extracellular space, apoplast.

Q&A

What is DIR22 Antibody and what is its target specificity?

DIR22 Antibody is a rabbit polyclonal antibody that targets the DIR22 protein (UniProt: Q66GI2) from Arabidopsis thaliana, a widely used model organism in plant biology . This antibody is generated using a recombinant Arabidopsis thaliana DIR22 protein as the immunogen and is purified using Protein A/G affinity chromatography . The antibody is specifically reactive to plant tissues and can be used to study DIR22 protein expression and localization in experimental systems .

What validated applications can DIR22 Antibody be used for?

Based on available data, DIR22 Antibody has been validated for the following applications:

ApplicationValidation StatusRecommended Dilution
Western Blot (WB)Validated1:500-1:2000
ELISAValidated1:1000-1:5000

These applications allow researchers to detect and quantify DIR22 protein in plant samples through different methodological approaches . When establishing these techniques in your laboratory, it is advisable to perform an antibody dilution series to determine optimal working concentrations for your specific experimental conditions.

What controls should be included when working with DIR22 Antibody?

For rigorous experimental design, the following controls should be incorporated:

  • Positive control: Use the provided recombinant immunogen protein/peptide (200μg) to confirm antibody binding specificity .

  • Negative control: The pre-immune serum provided in the antibody kit can serve as a negative control to detect non-specific binding .

  • Loading control: Include antibodies against constitutively expressed proteins (e.g., actin or tubulin) when performing Western blot analysis.

  • Knockout/knockdown samples: When available, samples from DIR22 knockout or knockdown plants provide valuable validation of antibody specificity.

Proper implementation of these controls ensures reliable interpretation of experimental results and helps troubleshoot potential issues.

How should DIR22 Antibody be stored and handled to maintain activity?

To preserve antibody functionality:

  • Store the antibody at -20°C or -80°C for long-term storage .

  • Avoid repeated freeze-thaw cycles by preparing small working aliquots.

  • Transport the antibody on blue ice when shipping between facilities .

  • When diluting the antibody, use buffers containing appropriate stabilizers (e.g., 1% BSA or 5% non-fat milk).

  • Record lot numbers and validation data to ensure experimental reproducibility.

Following these storage guidelines will help maintain antibody activity and ensure consistent experimental results across different time points.

How can I validate DIR22 Antibody specificity in my experimental system?

Rigorous validation of antibody specificity is critical for ensuring reliable research outcomes. Consider these approaches:

  • Western blot analysis: Compare band patterns between wild-type plants and DIR22 knockout/knockdown lines. A specific antibody will show reduced or absent signal in the knockout samples.

  • Peptide competition assay: Pre-incubate the antibody with excess immunizing peptide before application. Specific binding should be blocked, resulting in signal reduction.

  • Orthogonal detection methods: Confirm DIR22 protein expression using independent techniques such as mass spectrometry or RNA expression analysis.

  • Cross-reactivity assessment: Test the antibody against closely related proteins to determine potential cross-reactivity, particularly when studying conserved protein families.

Proper validation ensures that experimental observations genuinely reflect DIR22 biology rather than artifacts of non-specific antibody binding.

What are the best practices for optimizing DIR22 Antibody for Western blotting in plant tissues?

Plant tissues present unique challenges for Western blotting due to their high content of interfering compounds. Consider these optimization strategies:

  • Sample preparation optimization:

    • Add protease inhibitors and reducing agents to extraction buffers

    • Include polyvinylpolypyrrolidone (PVPP) to remove phenolic compounds

    • Perform TCA/acetone precipitation to concentrate proteins and remove contaminants

  • Blocking optimization:

    • Test different blocking agents (BSA, non-fat milk, commercial blockers)

    • Optimize blocking time (1-16 hours) and temperature (room temperature vs. 4°C)

  • Antibody incubation parameters:

    • Assess different dilutions of DIR22 Antibody (starting with 1:1000)

    • Compare overnight incubation at 4°C versus shorter incubations at room temperature

    • Add 0.05-0.1% Tween-20 to reduce background

  • Detection system selection:

    • Compare chemiluminescence, fluorescence, and colorimetric detection methods

    • Consider signal amplification systems for low-abundance targets

Systematic optimization of these parameters will yield cleaner, more specific Western blot results when working with plant tissues.

How do I troubleshoot non-specific binding when using DIR22 Antibody in ELISA?

When encountering high background or non-specific signals in ELISA applications:

  • Antibody dilution optimization: Create a dilution series (1:1000 to 1:10,000) to identify the optimal concentration balancing specific signal and background.

  • Blocking agent selection: Test several blocking agents (BSA, casein, commercial blockers) at different concentrations (1-5%) to identify the most effective option for your plant samples.

  • Wash buffer modifications:

    • Increase Tween-20 concentration (0.05-0.1%)

    • Add low salt concentrations (50-150mM NaCl) to reduce ionic interactions

    • Consider using specialized plant ELISA wash buffers containing additives to remove interfering compounds

  • Sample preparation refinement: Implement additional purification steps such as:

    • Buffer exchange using desalting columns

    • Pre-absorption with irrelevant proteins

    • Removal of plant-specific compounds that may interfere with antibody binding

A systematic troubleshooting approach examining each of these parameters will help resolve non-specific binding issues.

What considerations should be taken when designing immunoprecipitation experiments with DIR22 Antibody?

Immunoprecipitation (IP) with plant proteins requires specific considerations:

  • Crosslinking optimization: For studying protein-protein interactions, optimize crosslinking conditions specific to plant cell structures:

    • Test different crosslinkers (formaldehyde, DSP, DTSSP)

    • Determine optimal crosslinking time (5-30 minutes) and concentration

    • Establish effective quenching conditions

  • Extraction buffer selection:

    • Test different detergents (Triton X-100, NP-40, CHAPS) at various concentrations

    • Optimize salt concentrations to maintain interaction integrity

    • Include appropriate protease and phosphatase inhibitors

  • Antibody coupling strategies:

    • Direct coupling to beads using commercial kits

    • Sequential incubation with sample followed by Protein A/G beads

    • Pre-clearing samples to reduce non-specific binding

  • Elution condition optimization:

    • Compare different elution methods (pH, ionic strength, competitive elution)

    • Evaluate denaturing versus non-denaturing elution based on downstream applications

Carefully optimized IP protocols will enable successful isolation of DIR22 protein complexes for further analysis of interaction partners and post-translational modifications.

How does DIR22 function in Arabidopsis thaliana and what research questions remain open?

DIR22 (Dirigent protein 22) in Arabidopsis thaliana belongs to the dirigent protein family, which is involved in stereoselective coupling of monolignols during lignin biosynthesis and plant defense responses. Current research indicates several potential functions:

  • Lignin biosynthesis regulation: DIR proteins guide the stereochemistry of monolignol coupling, affecting lignin composition and structure in cell walls.

  • Stress response mediation: Evidence suggests DIR22 may be involved in plant responses to biotic and abiotic stresses, potentially through modulation of defense-related compounds.

  • Development regulation: Expression patterns indicate potential roles in specific developmental processes.

Open research questions that could be addressed using DIR22 Antibody include:

  • Spatiotemporal expression patterns of DIR22 during development and stress responses

  • Interaction partners of DIR22 during different physiological conditions

  • Post-translational modifications affecting DIR22 function

  • Subcellular localization and trafficking of DIR22 protein

Addressing these questions requires combining antibody-based approaches with genetic, biochemical, and physiological methodologies.

How should I design experiments to study DIR22 protein expression across different plant tissues and developmental stages?

To comprehensively characterize DIR22 expression patterns:

  • Tissue sampling strategy:

    • Harvest multiple tissue types (roots, stems, leaves, flowers, seeds)

    • Collect samples at defined developmental stages

    • Consider both normal and stress conditions

    • Immediately flash-freeze samples in liquid nitrogen

  • Protein extraction optimization:

    • Compare different extraction buffers for each tissue type

    • Adjust mechanical disruption methods based on tissue hardiness

    • Implement tissue-specific modifications to remove interfering compounds

  • Quantification approaches:

    • Western blotting with densitometry analysis

    • Quantitative ELISA

    • Immunohistochemistry with digital image analysis

  • Data normalization strategies:

    • Use multiple reference proteins as loading controls

    • Implement total protein normalization methods

    • Create standard curves using recombinant DIR22 protein

This systematic approach will generate a comprehensive atlas of DIR22 expression across plant development and in response to environmental stimuli.

What statistical approaches are appropriate for analyzing antibody-based quantitative data for DIR22?

Proper statistical analysis ensures rigorous interpretation of antibody-based quantification:

  • Exploratory data analysis:

    • Assess normality using Shapiro-Wilk test

    • Evaluate homogeneity of variance

    • Identify potential outliers

  • Statistical test selection:

    • Parametric tests (t-test, ANOVA) for normally distributed data

    • Non-parametric alternatives (Mann-Whitney, Kruskal-Wallis) when normality assumptions are violated

    • Mixed-effects models for complex experimental designs with repeated measures

  • Multiple comparison corrections:

    • Apply Bonferroni, Tukey, or FDR methods when comparing multiple conditions

    • Calculate confidence intervals to complement p-values

  • Power analysis:

    • Determine appropriate sample sizes for detecting biologically relevant differences

    • Consider variability observed in preliminary experiments

How does antibody-based detection of DIR22 compare with other protein detection methods?

Understanding the strengths and limitations of different detection methods enables selection of optimal approaches:

MethodSensitivitySpecificityQuantificationSpatial InformationTechnical Complexity
Western blot with DIR22 AntibodyHighMedium-HighSemi-quantitativeNoneMedium
ELISA with DIR22 AntibodyVery HighHighQuantitativeNoneMedium
ImmunohistochemistryMediumMediumSemi-quantitativeHighHigh
Mass SpectrometryVery HighVery HighQuantitativeLimitedVery High
RNA-Seq (mRNA level)HighHighQuantitativeLimitedHigh

For comprehensive studies, integration of multiple methods provides validation and complementary information about DIR22 biology.

How can I integrate DIR22 Antibody-based studies with transcriptomics and proteomics approaches?

Multi-omics integration offers comprehensive insights into DIR22 function:

  • Correlation analysis:

    • Compare DIR22 protein levels (detected by antibody) with mRNA expression

    • Identify conditions where post-transcriptional regulation may occur

    • Calculate protein-mRNA correlation coefficients across conditions

  • Co-expression network analysis:

    • Identify proteins and genes with expression patterns similar to DIR22

    • Build functional networks to predict biological roles

    • Use antibody-based confirmation of key network components

  • Integration of post-translational modifications:

    • Combine antibody-based detection with phospho-proteomics

    • Map modifications to functional domains

    • Assess impact on protein interactions and activity

  • Spatial context integration:

    • Combine bulk measurements with spatial techniques (immunohistochemistry)

    • Correlate tissue-specific expression with transcriptomic data

    • Develop computational methods to integrate spatial and molecular data

This integrated approach provides a systems-level understanding of DIR22 function in plant biology.

How can DIR22 Antibody be used in new research methodologies?

Emerging research techniques offer exciting possibilities for DIR22 investigation:

  • Proximity labeling applications:

    • Combine DIR22 Antibody with BioID or APEX2 systems

    • Identify transient interaction partners in living cells

    • Map the local protein environment of DIR22

  • Single-cell applications:

    • Adapt DIR22 Antibody for single-cell proteomics

    • Investigate cell-to-cell variability in DIR22 expression

    • Correlate with single-cell transcriptomics data

  • Super-resolution microscopy:

    • Optimize DIR22 Antibody labeling for STED, PALM, or STORM microscopy

    • Resolve subcellular localization at nanometer resolution

    • Track dynamic changes in DIR22 distribution

  • Live-cell imaging adaptations:

    • Develop cell-permeable antibody fragments for intracellular tracking

    • Monitor real-time changes in DIR22 localization

    • Combine with optogenetic approaches

These emerging methodologies expand the research toolkit available for studying DIR22 biology in increasingly sophisticated ways.

Quick Inquiry

Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
© Copyright 2025 TheBiotek. All Rights Reserved.